Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-26 (portalarauto.com.br)
Company based in Gauten receives contribution through the Tecnova/RS Program -
Biogen Biotechnological Solutions is a spinoff of Biosolar Environmental Solutions
Read more
2024-03-25 (yahoo.com)
Dyne Therapeutics Announces CEO Transition
John Cox John Cox, President and CEO of Dyne Therapeutics- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO- WALTHAM, Mass., March 25, 2024( GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.( Nasdaq: DYN), a clinical-stage muscle disease
Read more
2021-08-17 (fiercepharma.com)
Oracle of Organon: Buffett's Berkshire cashes out on Biogen, trims pharma holdings but discloses stake in Merck spinoff
Unlike other high-tech stocks such as Amazon and Apple where Warren Buffett is playing the long game, the Oracle of Omaha was apparently in Biogen for the short run. | Unlike other high-tech stocks such as Amazon and Apple where Warren Buffett is playing the long game, the Oracle of Omaha was
Read more
2018-01-31 (forbes.com)
Biogen Spin-Off Bioverativ To Be Acquired
Sanofi will acquire Bioverativ (BIVV) for $105 per share. Bioverativ spun from Biogen (BIIB) on Feb. 1, 2017. BIVV has returned 129%. Spin-Offs are 5x more likely to be acquired. Spin-Offs outperform the general market. Both this spin BIVV and BIIB are great examples of this over performance.
Read more
2016-11-18 (fiercebiotech.com)
Chutes & Ladders: Syntimmune taps Boehringer, Pfizer vet as new CEO
| Syntimmune appoints Boehringer, Pfizer alum David de Graaf as CEO, while Gilead promotes James Meyers, IDEXX Laboratories bids farewell to EVP Michael Williams and Biogen recruits two execs for to-be-launched hemophilia spinoff Bioverativ.
Read more
(biospace.com)
Biogen Spinoff Bioverativ Takes Out Bay Area’s True North in $825 Million Deal
May 23, 2017
Read more
(morningstar.com)
Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment
Biogen Inc. (BIIB) shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG (NOVN.EB) spinoff approval for the first biosimilar treatment of multiple sclerosis. The FDA granted approval to Sandoz Inc. for Tyruko, or natalizumab-sztn, the
Read more